Chronic hepatitis B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Chronic hepatitis B infection is
defined as HBsAg in the serum for six months. HBeAg and HBV DNA (measured using
a polymerase chain reaction (PCR) assay) are viral replication and infectivity
markers, whereas HBsAg is a hepatitis B viral infection marker. Cirrhosis,
liver failure, hepatocellular carcinoma, and death are severe complications of
chronic infection. HBV DNA can be found in the serum without HBeAg in a small
percentage of patients. The "precore" mutant in these patients
prevents completion and excretion of the "e" antigen despite active
HBV DNA replication and is linked to progressive liver disease.
- The risk for developing chronic hepatitis B after acute HBV
infection is age-dependent; approximately 90% of infants become
chronically infected, whereas only. Less than 5% of adults experience
chronic illness.
- If HBV transmission occurs at age ≤5 years, long‐term
consequences such as chronic hepatitis, cirrhosis, or HCC would be
significant problems.
Thelansis’s “Chronic hepatitis B Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Chronic
hepatitis B treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Chronic hepatitis B across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Chronic hepatitis B Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment